Distribuzione geografica
Continente #
NA - Nord America 2.055
EU - Europa 1.137
AS - Asia 162
SA - Sud America 4
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 3.366
Nazione #
US - Stati Uniti d'America 2.048
IE - Irlanda 767
CN - Cina 145
FI - Finlandia 110
DE - Germania 84
IT - Italia 79
SE - Svezia 17
BE - Belgio 13
RU - Federazione Russa 12
GB - Regno Unito 11
UA - Ucraina 10
FR - Francia 9
MK - Macedonia 9
CA - Canada 7
AT - Austria 6
IN - India 6
NL - Olanda 4
PH - Filippine 4
EU - Europa 3
RO - Romania 3
TR - Turchia 3
AR - Argentina 2
EG - Egitto 2
IR - Iran 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CO - Colombia 1
HK - Hong Kong 1
KZ - Kazakistan 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
Totale 3.366
Città #
Dublin 766
Chandler 536
Ashburn 253
Princeton 140
Lawrence 135
Medford 129
Wilmington 110
Helsinki 104
New York 77
Beijing 36
Pavia 29
Norwalk 27
Shanghai 25
Jacksonville 24
Washington 24
Nanjing 21
Fairfield 17
Woodbridge 16
Redwood City 14
Ann Arbor 13
Brussels 13
Milan 13
Hebei 11
Nanchang 9
Falls Church 7
Hangzhou 7
Seattle 7
Changsha 6
Toronto 6
Vienna 6
Dearborn 5
Jiaxing 5
San Francisco 5
Shenyang 5
New Delhi 4
Skopje 4
Berlin 3
Bologna 3
Chengdu 3
Eindhoven 3
Las Vegas 3
Monmouth Junction 3
Paris 3
Tianjin 3
Arcore 2
Bergamo 2
Biassono 2
Boardman 2
Borås 2
Buenos Aires 2
Chicago 2
Desio 2
Esslingen am Neckar 2
Falkenstein 2
Hefei 2
Hillsborough 2
Houston 2
Jinan 2
Manila 2
Redmond 2
Sant'Angelo Lodigiano 2
Scuola 2
Turin 2
Alba 1
Almaty 1
Ankara 1
Arnesano 1
Atlanta 1
Belfort 1
Belgrade 1
Cairo 1
Cambridge 1
Cheshunt 1
Corridonia 1
Council Bluffs 1
Dasmarinas 1
Des Moines 1
Duncan 1
Dundee 1
Fayetteville 1
Florence 1
Frankfurt am Main 1
Fremont 1
Fuzhou 1
Galati 1
Henderson 1
Kashan 1
Las Pinas 1
London 1
Melbourne 1
Messina 1
Montreal 1
Osimo 1
Perm 1
Pinehaven 1
Plovdiv 1
Prilep 1
Rockville 1
Rome 1
Sacramento 1
Totale 2.708
Nome #
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice 77
Drug eluting stents are superior to bare metal stents to reduce clinical outcome and stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis 61
Efficacy versus safety: The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease 58
Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events 55
Strategies for reducing door to balloon time in patients with acute myocardial infarction undergoing primary angioplasty: the Pavia experience 55
The prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy: An updated meta-analysis 52
Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesion–Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease 49
Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization : Analysis from the Apache study. 46
Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 45
Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis 43
DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients 42
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 40
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial 38
Alirocumab and cardiovascular outcomes after acute coronary syndrome 38
Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study 37
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 37
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX 36
APpropriAteness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: The APACHE pilot study 36
Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis 36
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial 35
Ticagrelor Alone or Conventional Dual Antiplatelet Therapy in Patients With Stable or Acute Coronary Syndromes 35
Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis 35
Clinical governance programme in patients with acute coronary syndrome: Design and methodology of a quality improvement initiative 35
Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis 34
Sotagliflozin in patients with diabetes and recent worsening heart failure 34
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 34
Parenteral antithrombotic therapy during primary percutaneous coronary intervention 33
Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 33
Myocarditis in a 16-year-old boy positive for SARS-CoV-2 32
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 32
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 32
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure 32
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets 32
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 32
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY 32
Aspirin Desensitization in Patients with Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). 31
Primum non nocere: An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes 31
Association of Troponin Levels with Mortality in Italian Patients Hospitalized with Coronavirus Disease 2019: Results of a Multicenter Study 31
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY 31
Around the clock, around the world-reflections on 24 hours of acute cardiovascular care 31
Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention 31
Early Complete Revascularization in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease 30
Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasivemanagement: Secondary analysis of a randomized clinical trial 30
Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial 30
Apixaban versus warfarin in patients with atrial fibrillation 30
2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group 30
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment 30
Acute Cardiovascular Care 2019 29
Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease 29
Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor? 29
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study 28
The prognostic value of serial troponin measurements in patients admitted for COVID-19 28
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol 28
Consistent Reduction in Periprocedural Myocardial Infarction with Cangrelor as Assessed by Multiple Definitions: Findings from CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) 27
Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes 27
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: Insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in Italian cardiac care units Registry 27
Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX) 27
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 27
Incidence of ventricular arrhythmias and 1-year predictors of mortality in patients treated with implantable cardioverter-defibrillator undergoing generator replacement 27
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis 27
Composition, structure, and function of heart teams: A joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization 26
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data 26
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 26
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study 26
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial 26
Antithrombotic Therapy in Patients With Acute Coronary Syndrome Complicated by Cardiogenic Shock or Out-Of-Hospital Cardiac Arrest: A Joint Position Paper From the European Society of Cardiology (ESC) Working Group on Thrombosis, in Association With the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) 26
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 25
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 25
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 25
Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed 25
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-st-segment elevation acute coronary syndrome (from the tracer trial) 25
The future for the Acute Cardiovascular Care Congress we shall find together 24
Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): Randomised controlled trial 24
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 24
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function 23
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes 23
Return towards normality in admissions for myocardial infarction after the lockdown removal for COVID-19 outbreak in Italy 23
Short-and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: Insights from four validated bleeding scales in the CHAMPION trials 23
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results from CHAMPION PHOENIX 22
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting 22
Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes 22
Prospective validation of the bleeding academic research consortium classification in the all-comer PRODIGY trial 22
Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the augustus trial 21
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome 21
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 21
Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score 21
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: Insights from the CHAMPION percutaneous coronary intervention trial 20
A novel approach to systematically implement the universal definition of myocardial infarction: Insights from the CHAMPION PLATFORM trial 20
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes 20
Clinical governance of patients with acute coronary syndromes 19
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: The GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) 19
Practical considerations for cangrelor use in patients with acute coronary syndromes 19
Use of biomarkers to predict specific causes of death in patients with Atrial fibrillation: Insights from the Aristotle Trial 19
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y 12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE-PCI trial 18
Reduction of Hospitalizations for Myocardial Infarction in Italy in the COVID-19 Era 18
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study 18
Protease-activated receptor-1 inhibitors: A novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome 17
Barriers associated with emergency medical service activation in patients with ST-segment elevation acute coronary syndromes 17
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization 16
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomised multicentre trial 16
Totale 3.012
Categoria #
all - tutte 19.119
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.119

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/2020240 27 41 1 5 6 2 0 7 2 22 14 113
2020/2021186 32 1 2 3 10 9 5 68 22 17 4 13
2021/2022589 20 33 8 8 10 5 12 35 26 9 86 337
2022/20231.767 228 138 18 88 114 140 3 89 877 15 38 19
2023/2024698 59 170 39 36 73 237 9 64 2 9 0 0
Totale 3.543